Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + carboplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cadonilimab (AK104) is a human tetravalent bispecific IgG1 antibody designed to simultaneously block the PD-1 and CTLA-4 immune checkpoints. It features an Fc-null design to minimize immune-related toxicities by eliminating Fc receptor-mediated effector functions such as ADCC, ADCP, CDC, and cytokine release. Cadonilimab is developed by Akeso and has demonstrated biological activity similar to the combination of separate anti-PD-1 and anti-CTLA-4 antibodies but with reduced toxicity. Carboplatin is a platinum-based chemotherapy agent that induces DNA crosslinking leading to apoptosis in cancer cells. Pemetrexed is an antifolate chemotherapeutic that inhibits multiple folate-dependent enzymes involved in nucleotide synthesis. The combination of these agents aims to enhance antitumor efficacy through both direct cytotoxic effects (carboplatin and pemetrexed) and immune modulation (cadonilimab). This regimen is under investigation for advanced solid tumors including non-small cell lung cancer[1][5][3].
- Other names
- cadonilimab + carboplatin + pemetrexed
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)GART (GAR transformylase)DHFR (Dihydrofolate reductase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cadonilimab + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + carboplatin + pemetrexed.